Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 9/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 9/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | XIAP | P98170 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29903199 | 1.00 | PDE5A (0.34) | PDE5AMTNR1AMTNR1BTYK2TSHR | |
| SCHEMBL24732163 | 0.81 | MTNR1A (0.44) | MTNR1AMTNR1BPDK2PDK4 | |
| SCHEMBL29903185 | 0.78 | BRD4 (0.35) | MTNR1ABRD4PDK2PDK4 | |
| SCHEMBL13920729 | 0.77 | TP53 (0.43) | — | |
| SCHEMBL5896773 | 0.76 | HDAC4 (0.40) | TSHR | |
| SCHEMBL3241787 | 0.76 | TP53 (0.44) | TSHR | |
| SCHEMBL3235237 | 0.72 | KMT2A (0.47) | — | |
| SCHEMBL24536430 | 0.72 | MEN1 (0.44) | TSHRBRD4PDK2PDK4 | |
| SCHEMBL3241986 | 0.69 | TP53 (0.43) | — | |
| SCHEMBL23044821 | 0.69 | PKM (0.47) | MTNR1ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348495-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | ASTEX THERAPEUTICS LIMITED (GB) | 2023-11-02 | — | — | US | disclosed |
| US-20230348495-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | ASTEX THERAPEUTICS LIMITED (GB) | 2023-11-02 | — | — | US | disclosed |
| US-20230348495-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | ASTEX THERAPEUTICS LIMITED (GB) | 2023-11-02 | — | — | US | disclosed |
| CN-115003677-A | Compounds having inhibitory activity against KRAS G12D mutation | 大鹏药品工业株式会社 | 2022-09-02 | — | — | CN | disclosed |
| WO-2021106231-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021107160-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021106231-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348495-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | KRAS, NRAS, HRAS | PDE5A 3988/4885MTNR1A 4481/4885MTNR1B 4232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.